FIELD: biotechnology.
SUBSTANCE: method includes low-virulent Group A MPK-12 β-haemolytic streptococci (Streptococcus pyogenes) live culture strain incubation in the liquid nutrient medium, followed by protective drying medium addition to the biomass containing a mixture of live bacteria and metabolic products. The vaccine in placed in ampoules and/or vials and lyophilisation is performed with subsequent sealing.
EFFECT: inventions can be used for prevention of streptococcal infections, prevention and treatment of oncological diseases, enzyme therapy, as well as an antiviral, thrombolytic and immunomodulating medication.
2 cl, 2 ex
